Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Identifying determinants of diabetes risk and outcomes for people with severe mental illness: a mixed-methods study›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Identifying determinants of diabetes risk and outcomes for people with severe mental illness: a mixed-methods study · References

References

CC BY 4.0 · NIHR Journals Library · approximately 29 min read

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). 5th edn. Washington, DC: American Psychiatric Publishing; 2013. 10.1176/appi.books.9780890425596
  2. World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. Geneva: WHO; 1992.
  3. The National Institute of Mental Health Information Resource Center. Mental Illness. 2019. URL: www.nimh.nih.gov/health/statistics/mental-illness.shtml#part_154784 (accessed November 2019).
  4. National Mental Health Intelligence Network. Severe Mental Illness (SMI) and Physical Health Inequalities: Briefing. London: Public Health England; 2018.
  5. NHS England. 2019/20 General Medical Services (GMS) Contract Quality and Outcomes Framework (QOF): Guidance for GMS Contract 201920 in England. London: NHS England; 2019.
  6. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016;388:86–97. 10.1016/S0140-6736(15)01121-626777917
  7. Thornicroft G, Tansella M, Becker T, Knapp M, Leese M, Schene A, Vazquez-Barquero JL, EPSILON Study Group. The personal impact of schizophrenia in Europe. Schizophr Res 2004;69:125–32. 10.1016/S0920-9964(03)00191-915469185
  8. Breslau J, Lane M, Sampson N, Kessler RC. Mental disorders and subsequent educational attainment in a US national sample. J Psychiatr Res 2008;42:708–16. 10.1016/j.jpsychires.2008.01.01618331741
  9. Levinson D, Lakoma MD, Petukhova M, Schoenbaum M, Zaslavsky AM, Angermeyer M, et al. Associations of serious mental illness with earnings: results from the WHO World Mental Health surveys. Br J Psychiatry 2010;197:114–21. 10.1192/bjp.bp.109.07363520679263
  10. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease study 2016. Schizophr Bull 2018;44:1195–203. 10.1093/schbul/sby05829762765
  11. Ferrari AJ, Stockings E, Khoo JP, Erskine HE, Degenhardt L, Vos T, Whiteford HA. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease study 2013. Bipolar Disord 2016;18:440–50. 10.1111/bdi.1242327566286
  12. National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults: Treatment and Management. NICE Clinical Guideline 178. 2014. URL: www.nice.org.uk/guidance/cg178/chapter/key-priorities-for-implementation (accessed November 2019).
  13. National Institute for Health and Care Excellence (NICE). Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. NICE Clinical Guideline 185. 2014. URL: www.nice.org.uk/guidance/cg185 (accessed November 2019).
  14. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull 2015;114:169–79. 10.1093/bmb/ldv01725957394
  15. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014;13:153–60. 10.1002/wps.2012824890068
  16. NHS Digital. 1.5.i Excess Under 75 Mortality Rate in Adults with Serious Mental Illness (Formerly Indicator 1.5). Leeds: NHS Digital; 2016.
  17. Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry 2017;211:175–81. 10.1192/bjp.bp.117.20260628684403
  18. Siddiqi N, Doran T, Prady SL, Taylor J. Closing the mortality gap for severe mental illness: are we going in the right direction? Br J Psychiatry 2017;211:130–1. 10.1192/bjp.bp.117.20302628864752
  19. Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019;6:675–712. 10.1016/S2215-0366(19)30132-431324560
  20. Reilly S, Olier I, Planner C, Doran T, Reeves D, Ashcroft DM, et al. Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK. BMJ Open 2015;5:e009010. 10.1136/bmjopen-2015-009010
  21. Link BG, Phelan J. Social conditions as fundamental causes of disease. J Health Soc Behav 1995;Spec:80–94. 10.2307/26269587560851
  22. Coid J, Gonzalez Rodriguez R, Kallis C, Zhang Y, Bhui K, De Stavola B, et al. Ethnic disparities in psychotic experiences explained by area-level syndemic effects [published online ahead of print 30 October 2019]. Br J Psychiatry 2019. 10.1192/bjp.2019.203
  23. Liu NH, Daumit GL, Dua T, Aquila R, Charlson F, Cuijpers P, et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry 2017;16:30–40. 10.1002/wps.2038428127922
  24. International Diabetes Federation (IDF). IDF Diabetes Atlas, 9th edn. Brussels: IDF; 2019.
  25. Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes. 5th edn. Chichester: John Wiley & Sons Ltd; 2017. 10.1002/9781444324808
  26. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005;67:152–62. 10.1016/j.diabres.2004.06.01015649575
  27. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–9. 10.1016/S0140-6736(08)60766-718502303
  28. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289–97. 10.1007/s00125-005-0097-z16391903
  29. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–50. 10.1056/NEJM20010503344180111333990
  30. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403. 10.1056/NEJMoa01251211832527
  31. NHS England. NHS Diabetes Prevention Programme (NHS DPP). 2019. URL: www.england.nhs.uk/diabetes/diabetes-prevention/ (accessed November 2019).
  32. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes in Adults: Management. NICE Guideline [NG28]. 2019. URL: www.nice.org.uk/guidance/ng28 (accessed April 2020).
  33. National Institute for Health and Care Excellence (NICE). Type 1 Diabetes in Adults: Diagnosis and Management: NICE Clinical Guideline NG17. 2016. URL: www.nice.org.uk/guidance/ng17 (accessed April 2020).
  34. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018;391:541–51. 10.1016/S0140-6736(17)33102-129221645
  35. Holt RI, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol 2015;11:79–89. 10.1038/nrendo.2014.20325445848
  36. Vancampfort D, Wampers M, Mitchell AJ, Correll CU, De Herdt A, Probst M, De Hert M. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013;12:240–50. 10.1002/wps.2006924096790
  37. Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 2017;74:261–9. 10.1001/jamapsychiatry.2016.380328097367
  38. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010;197:266–71. 10.1192/bjp.bp.109.07693520884948
  39. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010;35:1997–2004. 10.1038/npp.2010.7820520598
  40. Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 2016;73:247–59. 10.1001/jamapsychiatry.2015.292326792761
  41. Cohen D, Batstra MR, Gispen-de Wied CC. Immunological characteristics of diabetes in schizophrenia. Diabetologia 2005;48:1941–2. 10.1007/s00125-005-1879-z16052326
  42. McCreadie RG, Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534–9. 10.1192/03-16214645025
  43. Holt RIG, Gossage-Worrall R, Hind D, Bradburn MJ, McCrone P, Morris T, et al. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. Br J Psychiatry 2019;214:63–73. 10.1192/bjp.2018.16730251622
  44. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 2016;15:166–74. 10.1002/wps.2030927265707
  45. Citrome L, Kalsekar I, Baker RA, Hebden T. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Curr Med Res Opin 2014;30:1629–41. 10.1185/03007995.2014.90828024666104
  46. Yood MU, DeLorenze G, Quesenberry CP, Oliveria SA, Tsai AL, Willey VJ, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent – results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009;18:791–9. 10.1002/pds.178119526626
  47. Yood MU, DeLorenze GN, Quesenberry CP, Oliveria SA, Tsai A-L, Kim E, et al. Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC Psychiatry 2011;11:197. 10.1186/1471-244X-11-197
  48. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601. 10.2337/diacare.27.2.59614747245
  49. Holt RI, Peveler RC. Antipsychotic drugs and diabetes – an application of the Austin Bradford Hill criteria. Diabetologia 2006;49:1467–76. 10.1007/s00125-006-0279-316752165
  50. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951–62. 10.1016/S0140-6736(13)60733-323810019
  51. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123:225–33. 10.1016/j.schres.2010.07.01220692814
  52. Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 2017;40:771–81. 10.1007/s40264-017-0543-028585153
  53. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012;140:159–68. 10.1016/j.schres.2012.03.01722763424
  54. Naslund JA, Whiteman KL, McHugo GJ, Aschbrenner KA, Marsch LA, Bartels SJ. Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: a systematic review and meta-analysis. Gen Hosp Psychiatry 2017;47:83–102. 10.1016/j.genhosppsych.2017.04.00328807143
  55. de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 2016;16:341. 10.1186/s12888-016-1049-527716110
  56. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412–24. 10.1016/j.eurpsy.2009.01.00519682863
  57. Cooper SJ, Reynolds GP, Barnes T, England E, Haddad PM, Heald A, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016;30:717–48. 10.1177/026988111664525427147592
  58. Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005;19:102–9. 10.1177/0269881105059505
  59. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009;32:1037–42. 10.2337/dc08-172019244091
  60. Crawford MJ, Jayakumar S, Lemmey SJ, Zalewska K, Patel MX, Cooper SJ, Shiers D. Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study. Br J Psychiatry 2014;205:473–7. 10.1192/bjp.bp.113.14252125323141
  61. NHS Digital. Quality and Outcomes Framework (QOF) – 2014–15. 2015. URL: www.hscic.gov.uk/catalogue/PUB15751 (accessed May 2016).
  62. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010;196:116–21. 10.1192/bjp.bp.109.06751220118455
  63. Jones LE, Clarke W, Carney CP. Receipt of diabetes services by insured adults with and without claims for mental disorders. Med Care 2004;42:1167–75. 10.1097/00005650-200412000-0000315550796
  64. Holt RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep 2019;19:96. 10.1007/s11892-019-1220-831478094
  65. NHS England. Action for Diabetes. 2014. URL: www.england.nhs.uk/wp-content/uploads/2014/01/act-for-diabetes.pdf (accessed March 2017).
  66. Phelan JC, Link BG, Tehranifar P. Social conditions as fundamental causes of health inequalities: theory, evidence, and policy implications. J Health Soc Behav 2010;51:S28–40. 10.1177/002214651038349820943581
  67. World Health Organization (WHO). A Conceptual Framework for Action on the Social Determinants of Health. Geneva: WHO; 2010.
  68. Draine J, Salzer MS, Culhane DP, Hadley TR. Role of social disadvantage in crime, joblessness, and homelessness among persons with serious mental illness. Psychiatr Serv 2002;53:565–73. 10.1176/appi.ps.53.5.56511986504
  69. Cooper B. Schizophrenia, social class and immigrant status: the epidemiological evidence. Epidemiol Psichiatr Soc 2005;14:137–44. 10.1017/s1121189x0000638216255160
  70. Grigoroglou C, Munford L, Webb RT, Kapur N, Ashcroft DM, Kontopantelis E. Prevalence of mental illness in primary care and its association with deprivation and social fragmentation at the small-area level in England. Psychol Med 2020;50:293–302. 10.1017/S0033291719000023
  71. Koenders JF, de Mooij LD, Dekker JM, Kikkert M. Social inclusion and relationship satisfaction of patients with a severe mental illness. Int J Soc Psychiatry 2017;63:773–81. 10.1177/002076401773757229067839
  72. Wickham S, Taylor P, Shevlin M, Bentall RP. The impact of social deprivation on paranoia, hallucinations, mania and depression: the role of discrimination social support, stress and trust. PLOS ONE 2014;9:e105140. 10.1371/journal.pone.010514025162703
  73. Royal College of Psychiatrists. National Clinical Audit of Psychosis – National Report for the Core Audit 2018. London: Healthcare Quality Improvement Partnership; 2018.
  74. Eaton WW, Mortensen PB, Frydenberg M. Obstetric factors, urbanization and psychosis. Schizophr Res 2000;43:117–23. 10.1016/S0920-9964(99)00152-810858630
  75. Cooper B. Immigration and schizophrenia: the social causation hypothesis revisited. Br J Psychiatry 2005;186:361–3. 10.1192/bjp.186.5.36115863737
  76. Karlsen S, Nazroo JY, McKenzie K, Bhui K, Weich S. Racism, psychosis and common mental disorder among ethnic minority groups in England. Psychol Med 2005;35:1795–803. 10.1017/S003329170500583016194282
  77. Harrison G, Gunnell D, Glazebrook C, Page K, Kwiecinski R. Association between schizophrenia and social inequality at birth: case–control study. Br J Psychiatry 2001;179:346–50. 10.1192/bjp.179.4.34611581116
  78. Goulding SM, Holtzman CW, Trotman HD, Ryan AT, MacDonald AN, Shapiro DI, et al. The prodrome and clinical risk for psychotic disorders. Child Adolesc Psychiatr Clin N Am 2013;22:557–67. 10.1016/j.chc.2013.04.00224012073
  79. Topor A, Andersson G, Denhov A, Holmqvist S, Mattsson M, Stefansson C-G, et al. Psychosis and poverty: coping with poverty and severe mental illness in everyday life. Psychosis 2014;6:117–27. 10.1080/17522439.2013.790070
  80. DeVerteuil G, Hinds A, Lix L, Walker J, Robinson R, Roos LL. Mental health and the city: intra-urban mobility among individuals with schizophrenia. Health Place 2007;13:310–23. 10.1016/j.healthplace.2006.02.00116580246
  81. Pybus K, Pickett KE, Prady SL, Lloyd C, Wilkinson R. Discrediting experiences: outcomes of eligibility assessments for claimants with psychiatric compared with non-psychiatric conditions transferring to personal independence payments in England. BJPsych Open 2019;5:e19. 10.1192/bjo.2019.331068230
  82. Townshend T, Lake A. Obesogenic environments: current evidence of the built and food environments. Perspect Public Health 2017;137:38–44. 10.1177/175791391667986028449616
  83. Jones A, Bentham G, Foster C, Hillsdon M, Panter J. Tackling Obesities: Future Choices – Obesogenic Environments – Evidence Review. London: Government Office for Science; 2007.
  84. Link BG, Phelan JC. Conceptualizing stigma. Annu Rev Sociol 2001;27:363–85. 10.1146/annurev.soc.27.1.363
  85. O’Sullivan C, Thornicroft G, Layte R, Burfeind C, McDaid D, Salize H, et al. Background Document to the European Commission Thematic Conference. Lisbon: European Commission; 2010.
  86. Rüsch N, Thornicroft G. Does stigma impair prevention of mental disorders? Br J Psychiatry 2014;204:249–51. 10.1192/bjp.bp.113.13196124692749
  87. Gronholm PC, Thornicroft G, Laurens KR, Evans-Lacko S. Mental health-related stigma and pathways to care for people at risk of psychotic disorders or experiencing first-episode psychosis: a systematic review. Psychol Med 2017;47:1867–79. 10.1017/S003329171700034428196549
  88. Gallagher BJ, Jones BJ. Early-onset schizophrenia: symptoms and social class of origin. Int J Soc Psychiatry 2017;63:492–7. 10.1177/002076401771930228701088
  89. Freeman D, Emsley R, Dunn G, Fowler D, Bebbington P, Kuipers E, et al. The stress of the street for patients with persecutory delusions: a test of the symptomatic and psychological effects of going outside into a busy urban area. Schizophr Bull 2015;41:971–9. 10.1093/schbul/sbu17325528759
  90. Glick ID, Stekoll AH, Hays S. The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia. J Clin Psychopharmacol 2011;31:82–5. 10.1097/JCP.0b013e31820597fa21192148
  91. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP, Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70(Suppl. 4):1–46. 10.4088/JCP.7090su1cj19686636
  92. Preece J, Bimpson E. Housing Insecurity and Mental Health in Wales: An Evidence Review. Glasgow: UK Collaborative Centre for Housing Evidence; 2019.
  93. Moody A, Cowley G, Ng Fat L, Mindell JS. Social inequalities in prevalence of diagnosed and undiagnosed diabetes and impaired glucose regulation in participants in the Health Surveys for England series. BMJ Open 2016;6:e010155. 10.1136/bmjopen-2015-010155
  94. Dixon-Woods M, Cavers D, Agarwal S, Annandale E, Arthur A, Harvey J, et al. Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups. BMC Med Res Methodol 2006;6:35. 10.1186/1471-2288-6-3516872487
  95. Kontopantelis E, Stevens RJ, Helms PJ, Edwards D, Doran T, Ashcroft DM. Spatial distribution of clinical computer systems in primary care in England in 2016 and implications for primary care electronic medical record databases: a cross-sectional population study. BMJ Open 2018;8:e020738. 10.1136/bmjopen-2017-020738
  96. NHS Digital. Read Codes. 2018. URL: https://digital.nhs.uk/services/terminology-and-classifications/read-codes (accessed November 2019).
  97. Chisholm J. The Read clinical classification. BMJ 1990;300:1092. 10.1136/bmj.300.6732.10922344534
  98. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827–36. 10.1093/ije/dyv09826050254
  99. NHS Digital. Hospital Episode Statistics (HES). 2019. URL: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics (accessed September 2019).
  100. NHS Digital. Linked HES–ONS Mortality Data. 2018. URL: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/linked-hes-ons-mortality-data (accessed November 2019).
  101. Office for National Statistics. 2011 Census: Population and Household Estimates for Small Areas in England and Wales, March 2011. Newport: Office for National Statistics; 2012.
  102. Lad M. The English Indices of Deprivation 2010. London: Department for Communities and Local Government; 2011.
  103. Bellass S, Taylor J, Han L, Prady SL, Shiers D, Jacobs R, et al. Exploring severe mental illness and diabetes: protocol for a longitudinal, observational, and qualitative mixed methods study. JMIR Res Protoc 2019;8:13407. 10.2196/1340731493324
  104. National Institute for Health Research. Funding and Awards: Improving diabetes Outcomes for People with Severe Mental Illness (SMI): A Longitudinal Observational and Qualitative Study of Patients in England. URL: www.fundingawards.nihr.ac.uk/award/15/70/26 (accessed December 2019).
  105. Creswell JW. Research Design: Qualitative, Quantitative, and Mixed Methods Approaches. 4th edn. Thousand Oaks, CA: SAGE Publications, Inc.; 2014.
  106. Blaikie N. Approaches to Social Enquiry: Advancing Knowledge. 2nd edn. Cambridge: Polity; 2007.
  107. Fletcher AJ. Applying critical realism in qualitative research: methodology meets method. Int J Soc Res Methodol 2017;20:181–94. 10.1080/13645579.2016.1144401
  108. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008;337:a1655. 10.1136/bmj.a165518824488
  109. Gutacker N, Mason AR, Kendrick T, Goddard M, Gravelle H, Gilbody S, et al. Does the quality and outcomes framework reduce psychiatric admissions in people with serious mental illness? A regression analysis. BMJ Open 2015;5:e007342. 10.1136/bmjopen-2014-007342
  110. Kontopantelis E, Reeves D, Valderas JM, Campbell S, Doran T. Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study. BMJ Qual Saf 2013;22:53–64. 10.1136/bmjqs-2012-001033
  111. NHS Employers. 2016/17 General Medical Services (GMS) Contract Quality and Outcomes Framework (QOF): Guidance for GMS Contract 2016/17. Leeds: NHS Employers; 2016.
  112. Kronenberg C, Doran T, Goddard M, Kendrick T, Gilbody S, Dare CR, et al. Identifying primary care quality indicators for people with serious mental illness: a systematic review. Br J Gen Pract 2017;67:e519–e530. 10.3399/bjgp17X69172128673958
  113. Jacobs R, Aylott L, Dare C, Doran T, Gilbody S, Goddard M, et al. The association between primary care quality and health-care use, costs and outcomes for people with serious mental illness: a retrospective observational study. Health Serv Deliv Res 2020;8(25). 10.3310/hsdr08250
  114. Siddiqi N, Lewis H, Taylor J, Mahmoodi N, Wright J, McDermid K, et al. A systematic review of pharmacological and non-pharmacological interventions for improving diabetes outcomes in people with serious mental illness. PROSPERO 2015 CRD42015015558. URL: www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42015015558 (16 August 2020).
  115. Smith R, Han L, Ali S, Prady SL, Taylor J, Hughes T, et al. Glucose, cholesterol and blood pressure in type II diabetes: a longitudinal observational study comparing patients with and without severe mental illness. J Psychiatr Ment Health Nurs 2019;26:347–57. 10.1111/jpm.1254631287193
  116. Peek ME, Ferguson M, Bergeron N, Maltby D, Chin MH. Integrated community-healthcare diabetes interventions to reduce disparities. Curr Diab Rep 2014;14:467. 10.1007/s11892-013-0467-824464339
  117. Peek ME, Cargill A, Huang ES. Diabetes health disparities: a systematic review of health care interventions. Med Care Res Rev 2007;64(Suppl. 5):101–56. 10.1177/1077558707305409
  118. Ricci-Cabello I, Ruiz-Pérez I, Nevot-Cordero A, Rodríguez-Barranco M, Sordo L, Gonçalves DC. Health care interventions to improve the quality of diabetes care in African Americans: a systematic review and meta-analysis. Diabetes Care 2013;36:760–8. 10.2337/dc12-105723431094
  119. Ricci-Cabello I, Ruiz-Perez I, Rojas-García A, Pastor G, Gonçalves DC. Improving diabetes care in rural areas: a systematic review and meta-analysis of quality improvement interventions in OECD countries. PLOS ONE 2013;8:e84464. 10.1371/journal.pone.008446424367662
  120. Zeh P, Sandhu HK, Cannaby AM, Sturt JA. The impact of culturally competent diabetes care interventions for improving diabetes-related outcomes in ethnic minority groups: a systematic review. Diabet Med 2012;29:1237–52. 10.1111/j.1464-5491.2012.03701.x22553954
  121. Swinson Evans T, Berkman N, Brown C, Gaynes B, Palmieri Weber R. Disparities Within Serious Mental Illness. Technical Brief No. 25. Rockville, MD: Agency for Healthcare Research and Quality (US); 2016.
  122. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015;132:144–57. 10.1111/acps.1243925943829
  123. NHS Digital. National Diabetes Audit. Report 1: Care Processes and Treatment Targets, 2016–17: Severe Mental Illness – Supplementary Information. Leeds: NHS Digital; 2018.
  124. Smith DJ, Langan J, McLean G, Guthrie B, Mercer SW. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open 2013;3:e002808. 10.1136/bmjopen-2013-002808
  125. NHS Digital. ISB 0070: Healthcare Resource Groups (HRGs). 2018. URL: https://digital.nhs.uk/data-and-information/information-standards/information-standards-and-data-collections-including-extractions/publications-and-notifications/standards-and-collections/isb-0070-healthcare-resource-groups-hrgs (accessed December 2019).
  126. Ride J, Kasteridis P, Gutacker N, Aragon MJA, Jacobs R. Healthcare costs for people with serious mental illness in England: an analysis of costs across primary care, hospital care, and specialist mental healthcare. Appl Health Econ Health Policy 2020;18:177–88. 10.1007/s40258-019-00530-231701484
  127. Curtis LA, Burns A. Unit Costs of Health and Social Care 2018. Canterbury: Personal Social Services Research Unit, University of Kent; 2018.
  128. NHS Digital. Prescription Cost Analysis – England, 2018 [PAS]. URL: https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018 (accessed December 2019).
  129. NHS Digital. NHS Reference Costs 2017/18. 2018. URL: https://improvement.nhs.uk/resources/reference-costs/ (accessed 18 November 2019).
  130. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461–94. 10.1016/S0167-6296(01)00086-811469231
  131. Pregibon D. Goodness of link tests for generalized linear models. Appl Stat 1980;29:15–24. 10.2307/2346405
  132. Patton MQ. Qualitative Evaluation and Research Methods. Thousand Oaks, CA: SAGE Publications, Inc.; 1990.
  133. Taylor J, Lister J, Boehnke J, Holt R, Phillips A, Peyrot M, et al. The psychosocial impact of having diabetes alongside severe mental illness: comparing results from the Diabetes Attitudes, Wishes and Needs-Severe Mental Illness (DAWNSMI) and Diabetes Attitudes, Wishes and Needs Second (DAWN2) studies (conference abstract). Diabet Med 2019;36:9–11.30246418
  134. Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care 2010;48(Suppl. 6):114–20. 10.1097/MLR.0b013e3181dbebe3
  135. Davis L, Brekke J. Social support and functional outcome in severe mental illness: the mediating role of proactive coping. Psychiatry Res 2014;215:39–45. 10.1016/j.psychres.2013.09.01024113124
  136. Holt RI, Nicolucci A, Kovacs Burns K, Escalante M, Forbes A, Hermanns N, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2): cross-national comparisons on barriers and resources for optimal care – healthcare professional perspective. Diabet Med 2013;30:789–98. 10.1111/dme.1224223710839
  137. Reilly S, Planner C, Hann M, Reeves D, Nazareth I, Lester H. The role of primary care in service provision for people with severe mental illness in the United Kingdom. PLOS ONE 2012;7:e36468. 10.1371/journal.pone.003646822615769
  138. Pendlebury J, Holt RI. Managing diabetes in people with severe mental illness. J Diabetes Nurs 2010;14:328–39.
  139. Royal College of Psychiatrists. Report of the Second Round of the National Audit of Schizophrenia (NAS) 2014. London: Healthcare Quality Improvement Partnership; 2014.
  140. Arthur S, Nazroo J. Designing Fieldwork Strategies and Materials. In Ritchie J, Lewis J, editors. Qualitative Research Practice: A Guide for Social Science Students and Researchers. London: SAGE Publications Ltd; 2003. pp. 109–37.
  141. Ritchie J, Spencer L, O’Connor W. Carrying out Qualitative Analysis. In Ritchie J, Lewis J, editors. Qualitative Research Practice: A Guide for Social Science Students and Researchers. London: SAGE Publications Ltd; 2003. pp. 199–218.
  142. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 2013;13:117. 10.1186/1471-2288-13-11724047204
  143. Bellass S, Lister JE, Kitchen CEW, Kramer L, Alderson SL, Doran T, et al. Living with diabetes alongside a severe mental illness: a qualitative exploration with people with severe mental illness, family members and healthcare staff [published online ahead of print May 4 2021]. Diabet Med 2021. 10.1111/dme.14562
  144. NHS Digital. National Diabetes Audit, 2017–18. Report 1: Care Processes and Treatment Targets. 2019. URL: https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1-care-processes-and-treatment-targets-2017-18-full-report (accessed April 2020).
  145. Pearsall R, Shaw RJ, McLean G, Connolly M, Hughes KA, Boyle JG, et al. Health screening, cardiometabolic disease and adverse health outcomes in individuals with severe mental illness. BJPsych Open 2019;5:e97. 10.1192/bjo.2019.7631699180
  146. NHS Digital. National Diabetes Audit. Report 2: Complications and Mortality, 2017–18. URL: https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-2--complications-and-mortality-2017-18 (accessed April 2020).
  147. Das-Munshi J, Ashworth M, Dewey ME, Gaughran F, Hull S, Morgan C, et al. Type 2 diabetes mellitus in people with severe mental illness: inequalities by ethnicity and age. Cross-sectional analysis of 588 408 records from the UK. Diabet Med 2017;34:916–24. 10.1111/dme.1329827973692
  148. Walsan R, Mayne DJ, Feng X, Pai N, Bonney A. Examining the association between neighbourhood socioeconomic disadvantage and type 2 diabetes comorbidity in serious mental illness. Int J Environ Res Public Health 2019;16:E3905.31618833
  149. Wändell P, Ljunggren G, Wahlström L, Carlsson AC. Diabetes and psychiatric illness in the total population of Stockholm. J Psychosom Res 2014;77:169–73. 10.1016/j.jpsychores.2014.06.01225149026
  150. Cimo A, Dewa CS. Symptoms of mental illness and their impact on managing type 2 diabetes in adults. Can J Diabetes 2018;42:372–81. 10.1016/j.jcjd.2017.08.25629128304
  151. Stenov V, Willaing I, Knudsen L, Hansen DL, Joensen LE. Diabetes support needs in people with severe mental illness and diabetes. Diabetes 2019;68:837-P. 10.2337/db19-837-P30679183
  152. Mulligan K, McBain H, Lamontagne-Godwin F, Chapman J, Haddad M, Jones J, et al. Barriers and enablers of type 2 diabetes self-management in people with severe mental illness. Health Expect 2017;20:1020–30. 10.1111/hex.12543
  153. Mulligan K, McBain H, Lamontagne-Godwin F, Chapman J, Flood C, Haddad M, et al. Barriers to effective diabetes management – a survey of people with severe mental illness. BMC Psychiatry 2018;18:165. 10.1186/s12888-018-1744-529859061
  154. Ashworth M, Schofield P, Das-Munshi J. Physical health in severe mental illness. Br J Gen Pract 2017;67:436–7. 10.3399/bjgp17X69262128963399
  155. Fleetwood K, Wild S, Smith D, Licence K, Mercer S, Sudlow C, et al. OP47 The impact of major mental illness on quality of care in people with type 2 diabetes in Scotland: an analysis of routinely collected health data. J Epidemiol Community Health 2019;A23. 10.1136/jech-2019-SSMabstracts.48
  156. Brown K, Fortenberry K, Gren L, Gunning K, McAdam-Marx C. Achievement of adequate glycemic control in patients with type 2 diabetes and comorbid mental health conditions treated in a primary care setting. Diabetes Spectr 2017;30:277–87. 10.2337/ds16-003829151718
  157. Schulman-Marcus J, Goyal P, Swaminathan RV, Feldman DN, Wong SC, Singh HS, et al. Comparison of trends in incidence, revascularization, and in-hospital mortality in ST-elevation myocardial infarction in patients with versus without severe mental illness. Am J Cardiol 2016;117:1405–10. 10.1016/j.amjcard.2016.02.00626956637
  158. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128–36. 10.3399/bjgp10X48356220202356
  159. National Institute for Health and Care Excellence (NICE). Multimorbidity: Clinical Assessment and Management NICE Guideline (NG 56). 2016. URL: www.nice.org.uk/guidance/ng56 (accessed April 2020).
  160. Taylor J, Stubbs B, Hewitt C, Ajjan RA, Alderson SL Gilbody S, et al. The effectiveness of pharmacological and non-pharmacological interventions for improving glycaemic control in adults with severe mental illness: a systematic review and meta-analysis. PLOS ONE 2017;12:e0168549. 10.1371/journal.pone.016854928056018
  161. Gorczynski P, Firth J, Stubbs B, Rosenbaum S, Vancampfort D. Are people with schizophrenia adherent to diabetes medication? A comparative meta-analysis. Psych Res 2017;250:17–24. 10.1016/j.psychres.2017.01.049
  162. Charles EF, Lambert CG, Kerner B. Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications. Int J Bipolar Disord 2016;4:13. 10.1186/s40345-016-0054-427389787
  163. McGinty EE, Baller J, Azrin ST, Juliano-Bult D, Daumit GL. Interventions to address medical conditions and health-risk behaviors among persons with serious mental illness: a comprehensive review. Schizophr Bull 2016;42:96–124. 10.1093/schbul/sbv10126221050
  164. McBain H, Mulligan K, Haddad M, Flood C, Jones J, Simpson A. Self management interventions for type 2 diabetes in adult people with severe mental illness. Cochrane Database Syst Rev 2016;4:CD011361. 10.1002/14651858.CD011361.pub2
  165. McGinty EE, Baller J, Azrin ST, Juliano-Bult D, Daumit GL. Quality of medical care for persons with serious mental illness: a comprehensive review. Schizophr Res 2015;165:227–35. 10.1016/j.schres.2015.04.01025936686
  166. Ward M, Druss B. The epidemiology of diabetes in psychotic disorders. Lancet Psychiatry 2015;2:431–51. 10.1016/S2215-0366(15)00007-326360287
  167. Cimo A, Stergiopoulos E, Cheng C, Bonato S, Dewa CS. Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review. BMC Psychiatry 2012;12:24. 10.1186/1471-244X-12-2422443212
  168. Whitehead L. Self-management of type 2 diabetes and severe mental illness. Issues Ment Health Nurs 2017;38:606–7. 10.1080/01612840.2017.132885928613099
  169. Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry 2004;47:S67–71. 10.1192/bjp.184.47.s67
  170. Foley DL, Mackinnon A, Morgan VA, Watts GF, Castle DJ, Waterreus A, Galletly CA. Awareness of pre-diabetes or diabetes and associated factors in people with psychosis. Schizophr Bull 2016;42:1280–9. 10.1093/schbul/sbw02727150636
  171. Foley DL, Mackinnon A, Morgan VA, Watts GF, Castle DJ, Waterreus A, Galletly CA. Common familial risk factors for schizophrenia and diabetes mellitus. Aust N Z J Psychiatry 2016;50:488–94. 10.1177/000486741559571526209325
  172. Rathmann W, Pscherer S, Konrad M, Kostev K. Diabetes treatment in people with type 2 diabetes and schizophrenia: retrospective primary care database analyses. Prim Care Diabetes 2016;10:36–40. 10.1016/j.pcd.2015.04.00125937183
  173. Wake DJ, Broughton P, Perera SM, MacIntyre DJ, Leese GP. Altered metabolic parameters in association with antipsychotic medication use in diabetes: a population based case-control study. Psychoneuroendocrinology 2016;66:214–20. 10.1016/j.psyneuen.2016.01.02226849203
  174. Wu CS, Gau SS. Association between antipsychotic treatment and advanced diabetes complications among schizophrenia patients with type 2 diabetes mellitus. Schizophr Bull 2016;42:703–11. 10.1093/schbul/sbv18726721264
  175. Wykes TL, Lee AA, McKibbin CL, Laurent SM. Self-efficacy and hemoglobin a1c among adults with serious mental illness and type 2 diabetes: the roles of cognitive functioning and psychiatric symptom severity. Psychosom Med 2016;78:263–70. 10.1097/PSY.000000000000029527111458
  176. Foley DL, Mackinnon A, Morgan VA, Watts GF, Castle DJ, Waterreus A, Galletly CA. Effect of age, family history of diabetes, and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population-based cross-sectional study. Lancet Psychiatry 2015;2:1092–8. 10.1016/S2215-0366(15)00276-X26477242
  177. Wu CS, Lai MS, Gau SS. Complications and mortality in patients with schizophrenia and diabetes: population-based cohort study. Br J Psychiatry 2015;207:450–7. 10.1192/bjp.bp.113.14392526294369
  178. Foley DL, Mackinnon A, Morgan VA, Watts GF, McGrath JJ, Castle DJ, et al. Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis. World Psychiatry 2014;13:176–83. 10.1002/wps.2013024890070
  179. Chen SR, Chien YP, Kang CM, Jeng C, Chang WY. Comparing self-efficacy and self-care behaviours between outpatients with comorbid schizophrenia and type 2 diabetes and outpatients with only type 2 diabetes. J Psychiatr Ment Health Nurs 2014;21:414–22. 10.1111/jpm.1210123829198
  180. Mathur R, Hull SA, Boomla K, Robson J. Ethnic differences in primary care management of diabetes and cardiovascular disease in people with serious mental illness. Br J Gen Pract 2012;62:e582–8. 10.3399/bjgp12X65364222867683
  181. Schoepf D, Potluri R, Uppal H, Natalwala A, Narendran P, Heun R. Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. Eur Psychiatry 2012;27:33–42. 10.1016/j.eurpsy.2011.02.00921570814
  182. Becker T, Hux J. Risk of acute complications of diabetes among people with schizophrenia in Ontario, Canada. Diabetes Care 2011;34:398–402. 10.2337/dc10-113920978096
  183. Vinogradova Y, Coupland C, Hippisley-Cox J, Whyte S, Penny C. Effects of severe mental illness on survival of people with diabetes. Br J Psychiatry 2010;197:272–7. 10.1192/bjp.bp.109.07467420884949
  184. Whyte S, Penny C, Phelan M, Hippisley-Cox J, Majeed A. Quality of diabetes care in patients with schizophrenia and bipolar disorder: cross-sectional study. Diabet Med 2007;24:1442–8. 10.1111/j.1464-5491.2007.02324.x18042084
  185. McKibbin CL, Patterson TL, Norman G, Patrick K, Jin H, Roesch S, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res 2006;86:36–44. 10.1016/j.schres.2006.05.01016842977
  186. Dixon LB, Kreyenbuhl JA, Dickerson FB, Donner TW, Brown CH, Wohlheiter K, et al. A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses. Psychiatr Serv 2004;55:892–900. Erratum in: Psychiatr Serv 2004;55:1005. Dickerson, Faith B (corrected to Dickerson, Faith B); Wolheiter, Karen (corrected to Wohlheiter, Karen). 10.1176/appi.ps.55.8.89215292539
  187. Koro CE, Fedder DO, L’Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243. 10.1136/bmj.325.7358.24312153919
  188. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017;16:163–80. 10.1002/wps.2042028498599
  189. Pillinger T, Beck K, Stubbs B, Howes OD. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry 2017;211:339–49. 10.1192/bjp.bp.117.20090728982658
  190. Teasdale SB, Ward PB, Rosenbaum S, Samaras K, Stubbs B. Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiatry 2017;210:110–18. 10.1192/bjp.bp.115.17713927810893
  191. Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 2017;16:308–15. 10.1002/wps.2045828941119
  192. Stubbs B, Firth J, Berry A, Schuch FB, Rosenbaum S, Gaughran F, et al. How much physical activity do people with schizophrenia engage in? A systematic review, comparative meta-analysis and meta-regression. Schizophr Res 2016;176:431–40. 10.1016/j.schres.2016.05.01727261419
  193. Stubbs B, Williams J, Gaughran F, Craig T. How sedentary are people with psychosis? A systematic review and meta-analysis. Schizophr Res 2016;171:103–9. 10.1016/j.schres.2016.01.03426805414
  194. Hayes JF, Miles J, Walters K, King M, Osborn DP. A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr Scand 2015;131:417–25. 10.1111/acps.1240825735195
  195. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 2015;14:339–47. 10.1002/wps.2025226407790
  196. Rosenbaum S, Lederman O, Stubbs B, Vancampfort D, Stanton R, Ward PB. How can we increase physical activity and exercise among youth experiencing first-episode psychosis? A systematic review of intervention variables. Early Interv Psychiatry 2016;10:435–40. 10.1111/eip.1223825808450
  197. Happell B, Davies C, Scott D. Health behaviour interventions to improve physical health in individuals diagnosed with a mental illness: a systematic review. Int J Ment Health Nurs 2012;21:236–47. 10.1111/j.1447-0349.2012.00816.x22533331
  198. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011;68:609–16. 10.1001/archgenpsychiatry.2011.221300937
  199. Roberts SH, Bailey JE. Incentives and barriers to lifestyle interventions for people with severe mental illness: a narrative synthesis of quantitative, qualitative and mixed methods studies. J Adv Nurs 2011;67:690–708. 10.1111/j.1365-2648.2010.05546.x21323972
  200. Cabassa LJ, Ezell JM, Lewis-Fernández R. Lifestyle interventions for adults with serious mental illness: a systematic literature review. Psychiatr Serv 2010;61:774–82. 10.1176/ps.2010.61.8.77420675835
  201. Mitchell AJ, Malone D, Doebbeling CC. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry 2009;194:491–9. 10.1192/bjp.bp.107.04573219478286
  202. Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2015;2:452–64. 10.1016/S2215-0366(15)00115-726360288
  203. Nash M. Improving mental health service users’ physical health through medication monitoring: a literature review. J Nurs Manag 2011;19:360–5. 10.1111/j.1365-2834.2011.01244.x21507107
  204. Stubbs B, Chen LJ, Chung MS, Ku PW. Physical activity ameliorates the association between sedentary behavior and cardiometabolic risk among inpatients with schizophrenia: A comparison versus controls using accelerometry. Compr Psychiatry 2017;74:144–50. 10.1016/j.comppsych.2017.01.01028167327
  205. Das-Munshi J, Chang CK, Dutta R, Morgan C, Nazroo J, Stewart R, Prince MJ. Ethnicity and excess mortality in severe mental illness: a cohort study. Lancet Psychiatry 2017;4:389–99. 10.1016/S2215-0366(17)30097-428330589
  206. Osborn D, Marston L, Nazareth I, King MB, Petersen I, Walters K. Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine. Schizophr Res 2017;183:116–23. 10.1016/j.schres.2016.11.00927884434
  207. Stubbs B, Koyanagi A, Veronese N, Vancampfort D, Solmi M, Gaughran F, et al. Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. BMC Med 2016;14:189. 10.1186/s12916-016-0734-z27871281
  208. Vancampfort D, Guelinckx H, Probst M, Stubbs B, Rosenbaum S, Ward PB, De Hert M. Health-related quality of life and aerobic fitness in people with schizophrenia. Int J Ment Health Nurs 2015;24:394–402. 10.1111/inm.1214526215311
  209. Vancampfort D, De Hert M, Stubbs B, Ward PB, Rosenbaum S, Soundy A, Probst M. Negative symptoms are associated with lower autonomous motivation towards physical activity in people with schizophrenia. Compr Psychiatry 2015;56:128–32. 10.1016/j.comppsych.2014.10.00725458480
  210. Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013;368:1594–602. 10.1056/NEJMoa121453023517118
  211. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007;64:242–9. 10.1001/archpsyc.64.2.24217283292
  212. Worswick J, Wayne SC, Bennett R, Fiander M, Mayhew A, Weir MC, et al. Improving quality of care for persons with diabetes: an overview of systematic reviews – what does the evidence tell us? Syst Rev 2013;2:26. 10.1186/2046-4053-2-2623647654
  213. Lind M, Odén A, Fahlén M, Eliasson B. A systematic review of HbA1c variables used in the study of diabetic complications. Diabetes Metab Synd 2008;2:282–93. 10.1016/j.dsx.2008.04.006
  214. Steed L, Cooke D, Newman S. A systematic review of psychosocial outcomes following education, self-management and psychological interventions in diabetes mellitus. Patient Educ Couns 2003;51:5–15. 10.1016/s0738-3991(02)00213-612915275
  215. Betteridge J. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118(Suppl. 12A):10–15. 10.1016/j.amjmed.2005.09.01316356802
  216. Kontopantelis E, Springate DA, Reeves D, Ashcroft DM, Rutter MK, Buchan I, Doran T. Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. Diabetologia 2015;58:505–18. 10.1007/s00125-014-3473-825512005
  217. Nicolucci A, Kovacs Burns K, Holt RI, Comaschi M, Hermanns N, Ishii H, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabet Med 2013;30:767–77. 10.1111/dme.1224523711019
  218. Farmer A, Hardeman W, Hughes D, Prevost AT, Kim Y, Craven A, et al. An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes. BMC Fam Pract 2012;13:30. 10.1186/1471-2296-13-3022480341
  219. Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, et al. Diabetes Education and Self Management for Ongoing and Newly Diagnosed Collaborative. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008;336:491–5. 10.1136/bmj.39474.922025.BE18276664
  220. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89. 10.1056/NEJMoa080647018784090
  221. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med 2005;22:1379–85. 10.1111/j.1464-5491.2005.01644.x16176200
  222. Price HC, Ismail K. Royal College of Psychiatrists Liaison Faculty & Joint British Diabetes Societies (JBDS): guidelines for the management of diabetes in adults and children with psychiatric disorders in inpatient settings. Diabet Med 2018;35:997–1004. 10.1111/dme.1367330152583
  223. National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults. Quality standard [QS80]. URL: www.nice.org.uk/guidance/qs80 (accessed December 2019).
  224. National Institute for Health and Care Excellence. Type 2 Diabetes: Prevention in People at High Risk. Public health guideline [PH38]. URL: www.nice.org.uk/Guidance/PH38 (accessed December 2019).
  225. National Institute for Health and Care Excellence. Diabetes in Adults. Quality standard [QS6]. URL: www.nice.org.uk/Guidance/QS6 (accessed December 2019).
← DiscussionAcknowledgements →

Attribution. Jennie Lister; Lu Han; Sue Bellass; Jo Taylor; Sarah L Alderson; Tim Doran et al. (2021). Identifying determinants of diabetes risk and outcomes for people with severe mental illness: a mixed-methods study. NIHR Journals Library. Copyright © 2021 Lister et al. This work was produced by Lister et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited. Licensed under CC BY 4.0. NCBI Bookshelf NBK570523. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support